Roy Herbst, MD, PhD
Recent data have moved the needle across the board in oncology, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes. In a panel discussion at the 36th Annual CFS®, key opinion leaders in metastatic non–small cell lung cancer (NSCLC) and gastrointestinal cancer discussed how to distinguish between the available treatments and create a more personalized approach.
There have been a number of recent changes in the management of metastatic NSCLC, and the next challenge is determining an established standard for each line of therapy, said Roy S. Herbst, MD, PhD.
“Overall, these data with immunotherapy have been huge,” said Herbst. “Just last year, we still had pundits debating whether or not these agents would actually take over how we treat NSCLC. Now, there is no debate.”
Following the lung cancer portion of the session, Cathy Eng, MD, and David H. Ilson, MD, discussed the management of metastatic colorectal cancer (mCRC) and gastric cancer/gastroesophageal junction (GEJ) adenocarcinoma.
... to read the full story